Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15445132 | 0.84 | DPP4 (0.37) | DPP4EPHX1HPGDKDM4EL3MBTL1 | |
| SCHEMBL162904 | 0.80 | DPP4 (0.40) | DPP4EPHX1HPGDKDM4EL3MBTL1 | |
| SCHEMBL15747025 | 0.79 | ALDH1A1 (0.37) | DPP4EPHX1 | |
| SCHEMBL4547564 | 0.77 | DPP4 (0.37) | VDRDPP4CA12CA1CA2 | |
| SCHEMBL22384807 | 0.74 | VDR (0.34) | VDR | |
| SCHEMBL17125010 | 0.74 | TET2 (0.45) | DPP4EPHX1KDM4EBCHECA12 | |
| SCHEMBL23815728 | 0.74 | EPHX1 (0.37) | EPHX1BCHE | |
| SCHEMBL15445133 | 0.71 | VDR (0.33) | VDR | |
| SCHEMBL19942304 | 0.71 | ALDH1A1 (0.44) | DPP4EPHX1HPGD | |
| SCHEMBL10774381 | 0.71 | VDR (0.36) | VDRCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | PROTAGONIST THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-2900678-B1 | MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG | CENTRE NAT RECH SCIENT (FR) | 2020-09-02 | — | — | EP | disclosed |
| US-20170218085-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | NOVARTIS AG (CH) | 2017-08-03 | — | — | US | disclosed |
| US-20120015883-A1 | Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015883-A1 | Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same | APP, IAPP, PSEN1 | VDR 3144/4885DPP4 1327/4885EPHX1 3714/4885 |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | HAMP, VIP, HDGF | VDR 831/4885DPP4 841/4885EPHX1 2065/4885 |
| US-20170218085-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | PTMS, DNPEP, PSAT1 | VDR 3522/4885DPP4 620/4885EPHX1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.